Silence Therapeutics 将来の成長
Future 基準チェック /26
Silence Therapeuticsの収益は年間27.3%で減少すると予測されていますが、年間収益は年間56.2%で増加すると予測されています。EPS は年間 増加すると予測されています。自己資本利益率は 3 年後に-14.7% 20.2%なると予測されています。
主要情報
-27.3%
収益成長率
20.24%
EPS成長率
| Biotechs 収益成長 | 25.4% |
| 収益成長率 | 56.2% |
| 将来の株主資本利益率 | -14.73% |
| アナリストカバレッジ | Good |
| 最終更新日 | 21 May 2026 |
今後の成長に関する最新情報
分析記事 • Aug 12
Silence Therapeutics plc (NASDAQ:SLN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...分析記事 • May 11
Silence Therapeutics plc (NASDAQ:SLN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The analysts might have been a bit too bullish on Silence Therapeutics plc ( NASDAQ:SLN ), given that the company fell...分析記事 • Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
As you might know, Silence Therapeutics plc ( NASDAQ:SLN ) last week released its latest second-quarter, and things did...Recent updates
分析記事 • Feb 05
Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive
To the annoyance of some shareholders, Silence Therapeutics plc ( NASDAQ:SLN ) shares are down a considerable 27% in...分析記事 • Jan 31
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Nov 18
Silence Therapeutics: Divesiran Targets High-Burden PV
Summary Silence Therapeutics is advancing its lead RNAi drug, divesiran, for polycythemia vera, with a fully enrolled Phase 2 trial and results expected in Q3 2026. SLN boasts a strong cash position ($100M+), providing runway through 2028 and enabling continued pipeline development without near-term financing risks. The SANRECO trial's design and patient population position divesiran as a potential adjunctive therapy for high-burden PV patients, focusing on reduced phlebotomy frequency and infrequent dosing. While acknowledging clinical and market risks, I maintain a cautiously optimistic outlook, seeing significant upside if Phase 2 data demonstrate efficacy and safety. Read the full article on Seeking Alpha分析記事 • Oct 19
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Sep 28
Pinning Down Silence Therapeutics plc's (NASDAQ:SLN) P/S Is Difficult Right Now
With a median price-to-sales (or "P/S") ratio of close to 9.9x in the Biotechs industry in the United States, you could...分析記事 • Aug 13
Newsflash: Silence Therapeutics plc (NASDAQ:SLN) Analysts Have Been Trimming Their Revenue Forecasts
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...分析記事 • Aug 12
Silence Therapeutics plc (NASDAQ:SLN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:SLN 1 Year Share Price vs Fair Value Explore Silence Therapeutics's Fair Values from the Community and select...
ナラティブの更新 • Aug 08
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
The upward revision in Silence Therapeutics’ price target reflects significantly improved consensus revenue growth forecasts and a lower future P/E multiple, resulting in an increased fair value estimate from $32.37 to $37.26. What's in the News Silence Therapeutics approved the application of Article 159 of its articles of association, effective from the recent AGM to the next annual general meeting.分析記事 • May 11
Silence Therapeutics plc (NASDAQ:SLN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The analysts might have been a bit too bullish on Silence Therapeutics plc ( NASDAQ:SLN ), given that the company fell...分析記事 • May 06
Silence Therapeutics plc's (NASDAQ:SLN) Price Is Right But Growth Is Lacking After Shares Rocket 50%
Those holding Silence Therapeutics plc ( NASDAQ:SLN ) shares would be relieved that the share price has rebounded 50...
新しいナラティブ • Apr 01
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
The company's strategic partnerships and collaborations could reduce financial risk and enhance revenue growth through shared commercialization and milestone payments.分析記事 • Mar 22
Silence Therapeutics plc (NASDAQ:SLN) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Silence Therapeutics plc ( NASDAQ:SLN ) share price has dived 29% in the last...分析記事 • Mar 06
These Analysts Think Silence Therapeutics plc's (NASDAQ:SLN) Sales Are Under Threat
Market forces rained on the parade of Silence Therapeutics plc ( NASDAQ:SLN ) shareholders today, when the analysts...分析記事 • Mar 04
We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Jan 28
Risks Still Elevated At These Prices As Silence Therapeutics plc (NASDAQ:SLN) Shares Dive 26%
Unfortunately for some shareholders, the Silence Therapeutics plc ( NASDAQ:SLN ) share price has dived 26% in the last...分析記事 • Dec 10
Silence Therapeutics plc (NASDAQ:SLN) May Have Run Too Fast Too Soon With Recent 54% Price Plummet
Silence Therapeutics plc ( NASDAQ:SLN ) shareholders that were waiting for something to happen have been dealt a blow...分析記事 • Oct 04
Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio
You may think that with a price-to-sales (or "P/S") ratio of 38.4x Silence Therapeutics plc ( NASDAQ:SLN ) is a stock...分析記事 • Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
As you might know, Silence Therapeutics plc ( NASDAQ:SLN ) last week released its latest second-quarter, and things did...分析記事 • Jun 17
Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit
You may think that with a price-to-sales (or "P/S") ratio of 26.8x Silence Therapeutics plc ( NASDAQ:SLN ) is a stock...分析記事 • May 21
Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. By way of example, Silence...分析記事 • Feb 07
Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Silence Therapeutics plc ( NASDAQ:SLN ) shareholders will have a reason to smile today, with the analysts making...分析記事 • Nov 27
Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Silence Therapeutics plc ( NASDAQ:SLN ) shares have had a really impressive month, gaining 65% after a shaky period...Seeking Alpha • Sep 08
Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
U.K.-based clinical-stage biotech Silence Therapeutics plc (NASDAQ:SLN) announced Thursday that the FDA granted Fast Track Designation to SLN124 as a treatment for polycythemia vera (PV), a type of blood cancer. SLN124, belonging to a drug class called short interfering ribonucleic acid (siRNA) therapeutics, is set to undergo a Phase 1/2 study in PV this year. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling them to reach patients sooner. In a clinical trial last year, SLN124 indicated proof of mechanism and was well tolerated among healthy volunteers.Seeking Alpha • Aug 12
Silence Therapeutics prices 5.95M ADSs at $9.50/share
Silence Therapeutics (NASDAQ:SLN) has priced an underwritten offering of 5.95M American Depositary Shares, each representing three ordinary shares, at a price of $9.50/ADS, for aggregate gross proceeds of ~$56.5M. All of the ADSs are being offered by Silence. Offering is expected to close on or about August 16, 2022. Silence intends to use the net proceeds of the offering, together with its existing cash and cash equivalents to fund the advancement of its clinical trials, including its Phase 2 trial of SLN360 in ASCVD and its Phase 1/2 trial of SLN124 in polycythemia vera, as well as expansion of pipeline programs, working capital and general corporate purposes.業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 15 | -139 | -248 | -184 | 5 |
| 12/31/2027 | 6 | -108 | -199 | -132 | 5 |
| 12/31/2026 | 4 | -66 | -76 | -65 | 6 |
| 3/31/2026 | 1 | -75 | -66 | -66 | N/A |
| 12/31/2025 | 1 | -89 | -62 | -62 | N/A |
| 9/30/2025 | 26 | -65 | -73 | -72 | N/A |
| 6/30/2025 | 27 | -79 | -87 | -87 | N/A |
| 3/31/2025 | 28 | -72 | -71 | -71 | N/A |
| 12/31/2024 | 43 | -45 | -68 | -68 | N/A |
| 9/30/2024 | 18 | -73 | -53 | -53 | N/A |
| 6/30/2024 | 22 | -50 | -36 | -35 | N/A |
| 3/31/2024 | 33 | -44 | -49 | -49 | N/A |
| 12/31/2023 | 32 | -54 | -50 | -49 | N/A |
| 9/30/2023 | 34 | -52 | -50 | -50 | N/A |
| 6/30/2023 | 36 | -53 | -58 | -58 | N/A |
| 3/31/2023 | 29 | -53 | -48 | -48 | N/A |
| 12/31/2022 | 22 | -50 | -58 | -57 | N/A |
| 9/30/2022 | 18 | -40 | -39 | -38 | N/A |
| 6/30/2022 | 19 | -47 | -37 | -36 | N/A |
| 3/31/2022 | 20 | -51 | 4 | 6 | N/A |
| 12/31/2021 | 17 | -53 | 7 | 9 | N/A |
| 9/30/2021 | 15 | -57 | 4 | 5 | N/A |
| 6/30/2021 | 14 | -57 | 2 | 3 | N/A |
| 3/31/2021 | 11 | -49 | -33 | -32 | N/A |
| 12/31/2020 | 7 | -45 | -15 | -15 | N/A |
| 9/30/2020 | 4 | -33 | 0 | 1 | N/A |
| 6/30/2020 | 2 | -28 | 15 | 16 | N/A |
| 3/31/2020 | 1 | -26 | 9 | 9 | N/A |
| 12/31/2019 | 0 | -26 | N/A | 2 | N/A |
| 9/30/2019 | 0 | -23 | N/A | -10 | N/A |
| 6/30/2019 | N/A | -23 | N/A | -23 | N/A |
| 3/31/2019 | N/A | -24 | N/A | -23 | N/A |
| 12/31/2018 | N/A | -23 | N/A | -21 | N/A |
| 9/30/2018 | N/A | -15 | N/A | -20 | N/A |
| 6/30/2018 | N/A | -6 | N/A | -18 | N/A |
| 3/31/2018 | 0 | -4 | N/A | -17 | N/A |
| 12/31/2017 | 0 | -2 | N/A | -13 | N/A |
| 9/30/2017 | 1 | -7 | N/A | -12 | N/A |
| 6/30/2017 | 1 | -12 | N/A | -11 | N/A |
| 3/31/2017 | 1 | -11 | N/A | -12 | N/A |
| 12/31/2016 | 1 | -10 | N/A | -12 | N/A |
| 9/30/2016 | 0 | -10 | N/A | -13 | N/A |
| 6/30/2016 | N/A | -10 | N/A | -12 | N/A |
| 3/31/2016 | N/A | -10 | N/A | -13 | N/A |
| 12/31/2015 | N/A | -10 | N/A | -12 | N/A |
| 9/30/2015 | 0 | -12 | N/A | -13 | N/A |
| 6/30/2015 | 0 | -15 | N/A | -14 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: SLN今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: SLN今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: SLN今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: SLNの収益 ( 56.2% ) US市場 ( 11.6% ) よりも速いペースで成長すると予測されています。
高い収益成長: SLNの収益 ( 56.2% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: SLN 3 年以内に赤字になると予測されています。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 03:58 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Silence Therapeutics plc 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13
| アナリスト | 機関 |
|---|---|
| Howard Miller | Canaccord Genuity |
| Keay Nakae | Chardan Capital Markets, LLC |
| Nathaniel Calloway | Edison Investment Research |